Literature DB >> 9973365

Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance.

M Payton1, R Auty, R Delgoda, M Everett, E Sim.   

Abstract

Arylamine N-acetyltransferases (NATs) are found in many eukaryotic organisms, including humans, and have previously been identified in the prokaryote Salmonella typhimurium. NATs from many sources acetylate the antitubercular drug isoniazid and so inactivate it. nat genes were cloned from Mycobacterium smegmatis and Mycobacterium tuberculosis, and expressed in Escherichia coli and M. smegmatis. The induced M. smegmatis NAT catalyzes the acetylation of isoniazid. A monospecific antiserum raised against pure NAT from S. typhimurium recognizes NAT from M. smegmatis and cross-reacts with recombinant NAT from M. tuberculosis. Overexpression of mycobacterial nat genes in E. coli results in predominantly insoluble recombinant protein; however, with M. smegmatis as the host using the vector pACE-1, NAT proteins from M. tuberculosis and M. smegmatis are soluble. M. smegmatis transformants induced to express the M. tuberculosis nat gene in culture demonstrated a threefold higher resistance to isoniazid. We propose that NAT in mycobacteria could have a role in acetylating, and hence inactivating, isoniazid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9973365      PMCID: PMC93516          DOI: 10.1128/JB.181.4.1343-1347.1999

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  33 in total

1.  Genetic control of isoniazid metabolism in man.

Authors:  D A EVANS; K A MANLEY; V A McKUSICK
Journal:  Br Med J       Date:  1960-08-13

2.  Isonicotinic acid hypothesis of the antituberculous action of isoniazid.

Authors:  E THIEMER-KRUGER
Journal:  Am Rev Tuberc       Date:  1958-02

Review 3.  Proposed minimal standards for the genus Mycobacterium and for description of new slowly growing Mycobacterium species.

Authors:  V V Lévy-Frébault; F Portaels
Journal:  Int J Syst Bacteriol       Date:  1992-04

4.  Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver.

Authors:  S Ohsako; T Deguchi
Journal:  J Biol Chem       Date:  1990-03-15       Impact factor: 5.157

5.  Partial purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-aminosalicylic acid.

Authors:  J W Jennne
Journal:  J Clin Invest       Date:  1965-12       Impact factor: 14.808

Review 6.  N-acetylation pharmacogenetics.

Authors:  W W Weber; D W Hein
Journal:  Pharmacol Rev       Date:  1985-03       Impact factor: 25.468

7.  Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis.

Authors:  S B Snapper; R E Melton; S Mustafa; T Kieser; W R Jacobs
Journal:  Mol Microbiol       Date:  1990-11       Impact factor: 3.501

8.  Involvement of Cys69 residue in the catalytic mechanism of N-hydroxyarylamine O-acetyltransferase of Salmonella typhimurium. Sequence similarity at the amino acid level suggests a common catalytic mechanism of acetyltransferase for S. typhimurium and higher organisms.

Authors:  M Watanabe; T Sofuni; T Nohmi
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

9.  Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression.

Authors:  M Blum; D M Grant; W McBride; M Heim; U A Meyer
Journal:  DNA Cell Biol       Date:  1990-04       Impact factor: 3.311

10.  Arylamine N-acetyltransferase in human red blood cells.

Authors:  A Ward; D Hickman; J W Gordon; E Sim
Journal:  Biochem Pharmacol       Date:  1992-09-25       Impact factor: 5.858

View more
  31 in total

1.  Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid.

Authors:  C Deloménie; S Fouix; S Longuemaux; N Brahimi; C Bizet; B Picard; E Denamur; J M Dupret
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490

2.  Homology modelling and structural analysis of human arylamine N-acetyltransferase NAT1: evidence for the conservation of a cysteine protease catalytic domain and an active-site loop.

Authors:  F Rodrigues-Lima; C Deloménie; G H Goodfellow; D M Grant; J M Dupret
Journal:  Biochem J       Date:  2001-06-01       Impact factor: 3.857

3.  Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase.

Authors:  Isaac M Westwood; Simon J Holton; Fernando Rodrigues-Lima; Jean-Marie Dupret; Sanjib Bhakta; Martin E M Noble; Edith Sim
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

4.  Identification of metabolites produced from N-phenylpiperazine by Mycobacterium spp.

Authors:  M D Adjei; J Deck; T M Heinze; J P Freeman; A J Williams; J B Sutherland
Journal:  J Ind Microbiol Biotechnol       Date:  2006-12-22       Impact factor: 3.346

5.  Comparison of the Arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis.

Authors:  Elizabeth Fullam; Akane Kawamura; Helen Wilkinson; Areej Abuhammad; Isaac Westwood; Edith Sim
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

6.  Kinetic and chemical mechanism of arylamine N-acetyltransferase from Mycobacterium tuberculosis.

Authors:  Alison L Sikora; Brenda A Frankel; John S Blanchard
Journal:  Biochemistry       Date:  2008-09-17       Impact factor: 3.162

7.  Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis.

Authors:  James Sandy; Simon Holton; Elizabeth Fullam; Edith Sim; Martin Noble
Journal:  Protein Sci       Date:  2005-03       Impact factor: 6.725

8.  Mycobacterium tuberculosis Arylamine N-Acetyltransferase Acetylates and Thus Inactivates para-Aminosalicylic Acid.

Authors:  Xude Wang; Shanshan Yang; Jing Gu; Jiaoyu Deng
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

9.  Tuberculosis-spoligo-rifampin-isoniazid typing: an all-in-one assay technique for surveillance and control of multidrug-resistant tuberculosis on Luminex devices.

Authors:  Michel Kiréopori Gomgnimbou; Iván Hernández-Neuta; Stefan Panaiotov; Elizabeta Bachiyska; Juan Carlos Palomino; Anandi Martin; Patricia del Portillo; Guislaine Refregier; Christophe Sola
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

Review 10.  Arylamine N-acetyltransferases in mycobacteria.

Authors:  Edith Sim; James Sandy; Dimitrios Evangelopoulos; Elizabeth Fullam; Sanjib Bhakta; Isaac Westwood; Anna Krylova; Nathan Lack; Martin Noble
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.